A holistic approach to targeting disease with polymeric nanoparticles
Open accessThe DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Abstract
The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Encapsulation of hepcidin into biocompatible nanocarriers suitable for controlled release of therapeutics (Cheng et al., 2015) could theoretically address this issue.”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Cheng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Effect of Surface Properties on Nanoparticle–Cell Interactions
Verma, A., & Stellacci, F. (2010) · Small · doi:10.1002/smll.200901158 · Cited by 2,619
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 942
Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy
Yong, T., Zhang, X., Bie, N., Zhang, H., Zhang, X., Li, F., Hakeem, A., Hu, J., Gan, L., Santos, H. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11718-4 · Cited by 806
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Metadata
- Authors
- Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Saltzman, W. Mark
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-19
- Volume
- 14
- Issue
- 4
- Pages
- 239-247
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4451203
- OpenAlex
- W2041271505
- Cited by
- 480
- References
- 135
- Citations by year
- 2026: 13 · 2025: 37 · 2024: 31 · 2023: 41 · 2022: 42 · 2021: 37 · 2020: 42 · 2019: 40 · 2018: 46 · 2017: 63 · 2016: 60 · 2015: 27
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-04-30)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Cancer Institute (R01CA149128, F32CA174247, CA149128)
- National Institute of Allergy and Infectious Diseases (R01AI112443, T32AI089704, AI106992, R56AI106922, AI112443)
- National Institute of Biomedical Imaging and Bioengineering (EB00487, R01EB000487)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- targeted drug delivery, polymeric nanoparticles, nanomedicine, nanoparticle targeting, route of administration, nanoparticle design, clinical translation
- MeSH terms
- Animals, Humans, Polymers, Drug Delivery Systems, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A holistic approach to targeting disease with polymeric nanoparticles. https://app.cochat.ai/papers/10.1038/nrd4503
- The paper
- Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015). A holistic approach to targeting disease with polymeric nanoparticles. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.